Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis by Hezode, C, Dore, G, Pianko, S, Pol, S, Stuart, K, Thompson, A, Tse, E, Bhore, R, Jimenez-Exposito, M.J

Get full text

All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients with Advanced Fibrosis or Cirrhosis: An Analysis of Ally-3 and Ally-3 by Kowdley, K, Angus, P, Bernstein, D, Bronowicki, J.-P, Leroy, V, Pockros, P, Bhore, R, Rana, K, Jimenez-Exposito, M.J

Get full text

Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Progra... by Welzel, T, Petersen, J, Herzer, K, Ferenci, P, Gschwantler, M, Cornberg, M, Ingiliz, P, Berg, T, Spengler, U, Weiland, O, van der Valk, M, Klinker, H, Rockstroh, J, Peck-Radosavljevic, M, Zhao, Y, Jimenez-Exposito, M.J, Zeuzem, S

Get full text

Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compass... by Petersen, J, Welzel, T, Herzer, K, Ferenci, P, Gschwantler, M, Cornberg, M, Ingiliz, P, Berg, T, Spengler, U, Weiland, O, van der Valk, M, Klinker, H, Rockstroh, J, Peck-Radosavljevic, M, Zhao, Y, Jimenez-Exposito, M.J, Zeuzem, S

Get full text

P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use pro... by Welzel, T.M, Herzer, K, Ferenci, P, Petersen, J, Gschwantler, M, Cornberg, M, Berg, T, Spengler, U, Weiland, O, Van der Valk, M, Klinker, H, Rockstroh, J, Ingiliz, P, Peck-Radosavljevic, M, Jimenez-Exposito, M.J, Zeuzem, S

Get full text

SAT-129 - Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis by Hezode, C., Dore, G., Pianko, S., Pol, S., Stuart, K., Thompson, A., Tse, E., Bhore, R., Jimenez-Exposito, M.J.

Get full text

SAT-199 - All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients with Advanced Fibrosis or Cirrhosis: An Analysis of Ally-3 and Ally-3 by Kowdley, K., Angus, P., Bernstein, D., Bronowicki, J.-P., Leroy, V., Pockros, P., Bhore, R., Rana, K., Jimenez-Exposito, M.J.

Get full text

SAT-184 - Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicent... by Petersen, J., Welzel, T., Herzer, K., Ferenci, P., Gschwantler, M., Cornberg, M., Ingiliz, P., Berg, T., Spengler, U., Weiland, O., van der Valk, M., Klinker, H., Rockstroh, J., Peck-Radosavljevic, M., Zhao, Y., Jimenez-Exposito, M.J., Zeuzem, S.

Get full text

SAT-275 - Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate... by Welzel, T., Petersen, J., Herzer, K., Ferenci, P., Gschwantler, M., Cornberg, M., Ingiliz, P., Berg, T., Spengler, U., Weiland, O., van der Valk, M., Klinker, H., Rockstroh, J., Peck-Radosavljevic, M., Zhao, Y., Jimenez-Exposito, M.J., Zeuzem, S.

Get full text

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir‐boosted protease inhibitor in HIV/HCV‐coinfected drug‐naïve patients by Macías, J, Mallolas, J, López‐Cortés, LF, Cartón, JA, Domingo, P, Moreno, S, Iribarren, JA, Neukam, K, Rodrigo, A, Jiménez‐Expósito, MJ, Pineda, JA

Get full text